XAIR — Beyond Air, Inc.
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Company profile
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 107
- Website: https://www.beyondair.net
Latest SEC filings for XAIR
- EFFECT — 2026-08-25
- 8-K — 2026-08-18
- S-3 — 2026-08-17
- S-3 — 2026-08-17
- SCHEDULE 13G/A — 2026-08-14
- 10-Q — 2026-08-13
- 8-K — 2026-08-06
- 8-K — 2026-07-31
- 8-K — 2026-07-09
- 10-K — 2026-06-26
Latest XAIR news
- — Beyond Oil Appoints Joe Colligan as Chief Executive Officer of Beyond Oil USA (globenewswire.com)
- — Beyond Air expects revenue of $2.3M for quarter ended September 30 (seekingalpha_market)
- — Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 (globenewswire.com)
Educational tool only — not investment advice.